Menu
Search
|

Menu

Close
X

ESSA Pharma Inc EPIX.OQ (NASDAQ Stock Exchange Capital Market)

3.55 USD
+0.00 (+0.07%)
As of Jul 20
chart
Previous Close 3.55
Open 3.70
Volume 8,081
3m Avg Volume 3,925
Today’s High 3.70
Today’s Low 3.36
52 Week High 12.40
52 Week Low 2.78
Shares Outstanding (mil) 29.10
Market Capitalization (mil) 10.60
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-1.373
FY17
-3.330
FY16
-9.876
FY15
-10.958
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
--
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
--
16.84
LT Debt to Equity (MRQ)
vs sector
--
12.51
Return on Investment (TTM)
vs sector
-82.10
14.61
Return on Equity (TTM)
vs sector
-1,251.29
16.34

EXECUTIVE LEADERSHIP

Richard Glickman
Chairman of the Board, Since 2016
Salary: --
Bonus: --
David Parkinson
President, Chief Executive Officer, Director, Since 2016
Salary: --
Bonus: --
David Wood
Chief Financial Officer, Since
Salary: --
Bonus: --
Peter Virsik
Chief Operating Officer, Executive Vice President, Since 2016
Salary: --
Bonus: --
Raymond Andersen
Chief Technology Officer, Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

999 Broadway W Suite 720
VANCOUVER   BC   V5Z 1K5

Phone: +1778.3310962

ESSA Pharma Inc. is a Canada-based clinical-stage development pharmaceutical company. The Company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer (CRPC). The Company is developing drugs, which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR). The Company's product candidate, EPI-506 is a selective, oral small molecule pro-drug that blocks the N-terminal domain of the AR. EPI-506 is a pro-drug of EPI-002, a stereoisomer of the Company's discovery compound, EPI-001. The Company is conducting a Phase I/II clinical study to determine the safety, tolerability, maximum tolerated dose, pharmacokinetics and efficacy of EPI-506 in patients with metastatic CRPC. It is focused on developing EPI-506 as its clinical-development product candidate. ESSA Pharmaceuticals Corp. is the Company's subsidiary. The Company has not generated any revenues.

SPONSORED STORIES